News of Note—TapImmune, Hawaii Biotech and more

In this week's News of Note, TapImmune named a new CEO.

> Cancer vaccine biotech TapImmune named Peter Hoang as its next CEO. Release

> The University of Hawaii plus Soligenix and Hawaii Biotech won funding to work on a heat-stable Ebola vaccine candidate. Honolulu Civil Beat story

> AltImmune started enrollment on a phase 2 trial of its NasoVAX intranasal flu vaccine. Release

> Duke University secured a $41.5 million grant to oversee quality for NIH-supported HIV and AIDS research. Triangle Business Journal story

> EpiVax launched a dedicated cancer vaccine company with $500,000 in seed funding. Release